Symphogen taps Gallus for CMO work; WuXi, Clinipace name new execs;

> Symphogen has selected Gallus BioPharmaceuticals to manufacture antibody candidates for clinical trials. News

> WuXi PharmaTech ($WX) has appointed Hua Mu to serve as vice president of operations and head of product development. Mu has served stints at Roche ($RHHBY), Biogen Idec ($BIIB) and China's Hutchison MediPharma. More

> Clinipace has picked Lee Schacter to be its next executive medical director, bringing experience from Johnson & Johnson ($JNJ), AstraZeneca ($AZN) and Pfizer ($PFE). Item

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.